CyBorD regimen shows promise against AL amyloidosis

Published on February 14, 2012 at 1:06 AM · No Comments

A Mayo Clinic-led study, published in the American Society of Hematology (ASH) journal Blood http://bloodjournal.hematologylibrary.org/ found that CyBorD, a triple chemotherapy drug combination that has been successful in helping patients with the blood cancer multiple myeloma, also showed promise in improving the care for patients with the rare blood disease AL amyloidosis.

AL amyloidosis is an incurable disease in which abnormal proteins produced in the bone marrow travel to major organs of the body, leaving deposits that typically damage the heart and kidneys. The median overall survival for those with this disease is approximately three years. For those where the disease causes heart damage, the overall survival is less than a year.

"This novel drug combination was able to effectively shut off the production of the abnormal proteins," says the study's lead researcher Joseph Mikhael, M.D., a hematologist at Mayo Clinic in Arizona.

Click here as Dr. Mikhael explains the study

Prior to the CyBorD regimen, those with AL amyloidosis had few effective treatment options to keep the disease in check, explains Dr. Mikhael. "What we found remarkable was how fast the combination worked — the average time to response was less than two months," he says. "Furthermore, over 90 percent of patients had at least a 50 percent drop in the protein, with over 70 percent having the protein disappear entirely."

Typically, treatment includes a lengthy regimen of chemotherapy and possibly a stem cell transplant for those few patients who meet the medical criteria to receive a transplant.

CyBorD treatment consists of the drugs cyclophosphamide, bortezomib and dexamethasone. The research found that this treatment:

  • Rapidly reduced the amount of abnormal proteins
  • Was easier for patients to tolerate, compared to the previous chemotherapy protocol used
  • Could be used in patients who were eligible and ineligible for transplant
  • Was effective as a first-line treatment and also in relapsed disease
Source:

Mayo Clinic

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients